Oncotarget. 2025 Mar 12;16:140-162. doi: 10.18632/oncotarget.28703.
ABSTRACT
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine founded by Drs. John Mendelsohn and Thomas Tursz provided a vision for innovation, collaboration and global impact in precision oncology. Through pursuit of transcriptomic signatures, artificial intelligence (AI) algorithms, global precision cancer medicine clinical trials and input from an international Molecular Tumor Board (MTB), WIN has led the way in demonstrating patient benefit from precision-therapeutics through N-of-1 molecularly-driven studies. WIN Next-Generation Precision Oncology (WINGPO) trials are being developed in the neoadjuvant, adjuvant or metastatic settings, incorporate real-world data, digital pathology, and advanced algorithms to guide MTB prioritization of therapy combinations for a diverse global population. WIN has pursued combinations that target multiple drivers/hallmarks of cancer in individual patients. WIN continues to be impactful through collaboration with industry, government, sponsors, funders, academic and community centers, patient advocates, and other stakeholders to tackle challenges including drug access, costs, regulatory barriers, and patient support. WIN's collaborative next generation of precision oncology trials will guide treatment selection for patients with advanced cancers through MTB and AI algorithms based on serial liquid and tissue biopsies and exploratory omics including transcriptomics, proteomics, metabolomics and functional precision medicine. Our vision is to accelerate the future of precision oncology care.
PMID:40073368 | PMC:PMC11907938 | DOI:10.18632/oncotarget.28703
Nature, Published online: 04 March 2025; doi:10.1038/d41586-025-00618-x
As the European Union’s Artificial Intelligence Act takes effect, AI systems that mimic how human teams collaborate can improve trust in high-risk situations, such as clinical medicine.
STAR Protoc. 2025 Feb 11;6(1):103635. doi: 10.1016/j.xpro.2025.103635. Online ahead of print.
ABSTRACT
We introduce a protocol for generating 3D organoids from circulating tumor cells (CTCs), enabling longitudinal functional and molecular analyses in pancreatic cancer patients, including those with unresectable disease, which constitutes the majority of cases. We outline the process for isolating and characterizing CTCs from the blood of pancreatic cancer patients and provide detailed instructions for initiating, passaging, and phenotyping CTC-derived organoids. Additionally, we describe techniques for utilizing these organoids in drug screening with a focus on stemness-related pathways. For complete details on the use and execution of this protocol, please refer to Tang et al.1.
PMID:39946239 | PMC:PMC11870243 | DOI:10.1016/j.xpro.2025.103635
The panelists discuss how generative AI is boosting productivity, redefining the developer experience, and affecting software development in 2025.
By Christian Bonzelet, Jessica Andersson, Garima Bajpai, Shobhit Verma, Renato Losio
Oncogene, Published online: 17 January 2025; doi:10.1038/s41388-024-03270-3
Evidence of DNA methylation heterogeneity and epipolymorphism in kidney cancer tissue samples
Nature, Published online: 08 January 2025; doi:10.1038/s41586-024-08300-4
We discuss the potential consequences and ethical concerns of polygenic genome editing of human embryos to alter specific variants associated with polygenic diseases, highlighting the possibility of reducing disease susceptibility while exacerbating health inequalities.
Nature, Published online: 08 January 2025; doi:10.1038/s41586-024-08388-8
Results from a comprehensive evaluation of the function of BRCA2 variants, particularly variants of uncertain significance, provide a useful resource to improve the clinical management of individuals who carry such genetic variants.
Nature, Published online: 08 January 2025; doi:10.1038/s41586-024-08377-x
A study identifies three dominant genomic archetypes of breast cancer induced by discrete mutational processes, describing a continuum of genomic profiles and detailing the mechanisms underlying the progression of breast cancer.
Nature, Published online: 01 January 2025; doi:10.1038/s41586-024-08275-2
Twigstats, a method for ancestry reconstruction, provides high-resolution genetic histories and movement patterns of people living in Europe during the first millennium ce.
Nature, Published online: 23 December 2024; doi:10.1038/s41586-024-08555-x
Author Correction: π-HuB: the proteomic navigator of the human body
Nature, Published online: 18 December 2024; doi:10.1038/s41586-024-08333-9
Motif grammar on nucleosome fibres acts as signpost elements, directing TF combinatorial binding to enhancers.
Nature, Published online: 15 May 2024; doi:10.1038/s41586-024-07302-6
This Review discusses the importance of genetic and non-genetic reprogramming events during the metastatic cascade.
Nature, Published online: 13 March 2024; doi:10.1038/s41586-024-07177-7
We uncover key processes of the genomic evolution of small cell lung cancer under therapy, identify the common ancestor as the source of clonal diversity at relapse and show central genomic patterns associated with drug response.
Cell Death Discovery, Published online: 13 March 2024; doi:10.1038/s41420-024-01863-1
Ferroptosis: a new hunter of hepatocellular carcinoma
Nature, Published online: 06 March 2024; doi:10.1038/s41586-024-07148-y
A meta-analysis of genome-wide association studies for 233 circulating metabolites from 33 cohorts reveals more than 400 loci and suggests probable causal genes, providing insights into metabolic pathways and disease aetiology.
Login